US company Johnson & Johnson has kicked off its Phase 3 trials of a possible single-shot COVID-19 vaccine, the company said in a press release on Wednesday.
This large-scale, pivotal, multi-country Phase 3 trial for the COVID-19 vaccine candidate, JNJ-78436735, is developed by the Janssen Pharmaceutical Companies, the release said.
The final stage of the study will be conducted on 60,000 adult volunteers in the United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa, the release said.
The Johnson & Johnson single-dose shot is the fourth vaccine candidate to enter late-stage testing in the United States, after Moderna, Pfizer/BioNTech and AstraZeneca began similar trials.
The company plans to include in its study members of populations that have been disproportionately affected by the COVID-19, including Black, Hispanic, American Indian and Alaskan Native volunteers, it added.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.